CCDC86 and diffuse large B-cell lymphoma: Nuclear protein CYCLON and nucleolar multifunctional protein NPM1 were found to be associated with DLBCL advance and anti-CD20 therapy resistance, which may be potential novel targets for DLBCL treatment [17].